NDC Code(s) : 55513-160-01
Packager : Amgen Inc
Category : HUMAN PRESCRIPTION DRUG LABEL
DEA Schedule : none
Marketing Status : New Drug Application
INGREDIENTS AND APPEARANCE
BLINCYTOblinatumomab KIT | ||||||||||||||||||||||||
|
||||||||||||||||||||||||
|
||||||||||||||||||||||||
|
||||||||||||||||||||||||
|
LABELER - Amgen Inc(039976196) |
Establishment | |||
Name | Address | ID/FEI | Business Operations |
Eurofins PROXY Laboratories B.V. | 490477955 | ANALYSIS(55513-160) |
PRINCIPAL DISPLAY PANEL
AMGEN®
35
mcg/vial
1 BLINCYTO® Single-Dose Vial
1 IV Solution Stabilizer Vial
NDC 55513-160-01
BLINCYTO®
(blinatumomab)
for Injection
35 mcg/vial
For Intravenous Infusion Only
Store refrigerated at 2°C to 8°C (36°F to 46°F).
Store in carton to protect from light.
DO NOT SHAKE reconstituted solution.
Dispense the enclosed Medication Guide to each patient.
No Preservative
Single-Dose Vial –
Discard unused portion.
Rx Only